Clear All
11888 Matching Results — Export these results
Click column titles once to sort ascending, and twice to sort descending.
NDC-11 (Package) NDC-9 (Product) Generic Name Brand Name Strength SEER*Rx Category Major Class Minor Class Administration Route Package Effective Date Package Discontinuation Date Status
68475-0509-01 68475-0509 Fosaprepitant Fosaprepitant 150.0 mg/5mL Ancillary Therapy Antiemetic Substance P/Neurokinin 1 Intravenous Jun 8, 2022 In Use
68001-0517-36 68001-0517 fosaprepitant fosaprepitant 150.0 mg/5mL Ancillary Therapy Antiemetic Substance P/Neurokinin 1 Intravenous Aug 23, 2021 Jul 31, 2024 No Longer Used
16714-0120-01 16714-0120 Fosaprepitant Fosaprepitant 150.0 mg/5mL Ancillary Therapy Antiemetic Substance P/Neurokinin 1 Intravenous Jan 16, 2020 In Use
81952-0911-01 81952-0911 FOSAPREPITANT FOSAPREPITANT 150.0 mg/5mL Ancillary Therapy Antiemetic Substance P/Neurokinin 1 Intravenous Jul 14, 2023 In Use
72606-0569-01 72606-0569 Fosaprepitant Dimeglumine Fosaprepitant 150.0 mg/5mL Ancillary Therapy Antiemetic Substance P/Neurokinin 1 Intravenous Mar 1, 2020 In Use
31722-0165-31 31722-0165 Fosaprepitant dimeglumine Fosaprepitant 150.0 mg/5mL Ancillary Therapy Antiemetic Substance P/Neurokinin 1 Intravenous Jul 29, 2021 In Use
72205-0054-01 72205-0054 Fosaprepitant Fosaprepitant 150.0 mg/5mL Ancillary Therapy Antiemetic Substance P/Neurokinin 1 Intravenous May 12, 2020 In Use
00781-3497-75 00781-3497 Fosaprepitant Fosaprepitant 150.0 mg/5mL Ancillary Therapy Antiemetic Substance P/Neurokinin 1 Intravenous Sep 2, 2020 Feb 29, 2024 No Longer Used
70860-0782-10 70860-0782 Fosaprepitant dimeglumine Fosaprepitant 150.0 mg/5mL Ancillary Therapy Antiemetic Substance P/Neurokinin 1 Intravenous Nov 30, 2020 Jan 31, 2023 No Longer Used
45629-0089-01 45629-0089 Tivozanib FOTIVDA 0.89 mg/1 Chemotherapy Tyrosine Kinase Inhibitor VEGFR Oral Mar 10, 2021 In Use
45629-0134-02 45629-0134 Tivozanib FOTIVDA 1.34 mg/1 Chemotherapy Tyrosine Kinase Inhibitor VEGFR Oral Jan 30, 2025 In Use
45629-0134-01 45629-0134 Tivozanib FOTIVDA 1.34 mg/1 Chemotherapy Tyrosine Kinase Inhibitor VEGFR Oral Mar 10, 2021 In Use
45629-0089-02 45629-0089 Tivozanib FOTIVDA 0.89 mg/1 Chemotherapy Tyrosine Kinase Inhibitor VEGFR Oral Jan 30, 2025 In Use
83831-0121-04 83831-0121 Cyclophosphamide Frindovyx 2.0 g/4mL Chemotherapy Alkylating Agent Nitrogen Mustard Intravenous Mar 19, 2025 In Use
83831-0119-01 83831-0119 Cyclophosphamide Frindovyx 500.0 mg/mL Chemotherapy Alkylating Agent Nitrogen Mustard Intravenous Mar 19, 2025 In Use
83831-0120-02 83831-0120 Cyclophosphamide Frindovyx 1.0 g/2mL Chemotherapy Alkylating Agent Nitrogen Mustard Intravenous Mar 19, 2025 In Use
63020-0225-21 63020-0225 Fruquintinib Fruzaqla 5.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor VEGFR Oral Nov 8, 2023 In Use
63020-0210-21 63020-0210 Fruquintinib Fruzaqla 1.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor VEGFR Oral Nov 8, 2023 In Use
67457-0833-06 67457-0833 Pegfilgrastim Fulphila 6.0 mg/.6mL Ancillary Therapy Immunostimulant Granulocyte Colony-Stimulating Factor Subcutaneous Jul 9, 2018 May 31, 2026 In Use
83257-0005-41 83257-0005 Pegfilgrastim-jmdb Fulphila 6.0 mg/.6mL Ancillary Therapy Immunostimulant Granulocyte Colony-Stimulating Factor Subcutaneous Oct 1, 2023 In Use
68001-0522-85 68001-0522 Fulvestrant FULVESTRANT 250.0 mg/5mL Hormonal Therapy Estrogen Receptor Antagonist Intramuscular Oct 29, 2021 In Use
68001-0484-85 68001-0484 Fulvestrant Fulvestrant 250.0 mg/5mL Hormonal Therapy Estrogen Receptor Antagonist Intramuscular Mar 1, 2021 In Use
00143-9022-02 00143-9022 Fulvestrant Fulvestrant 50.0 mg/mL Hormonal Therapy Estrogen Receptor Antagonist Intramuscular Feb 10, 2022 In Use
70700-0284-98 70700-0284 fulvestrant FULVESTRANT 50.0 mg/mL Hormonal Therapy Estrogen Receptor Antagonist Intramuscular Aug 19, 2021 In Use
70860-0211-74 70860-0211 Fulvestrant Fulvestrant 50.0 mg/mL Hormonal Therapy Estrogen Receptor Antagonist Intramuscular Feb 18, 2020 Dec 31, 2026 In Use

Found 11888 results — Export these results